Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune Modulation in Lung Cancer: Current Concepts and Future Strategies
Lena Gaissmaier, Petros Christopoulos
Respiration (2020) Vol. 99, Iss. 11, pp. 903-929
Open Access | Times Cited: 23

Showing 23 citing articles:

Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer
Mariam Elshiaty, Hannah Schindler, Petros Christopoulos
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5632-5632
Open Access | Times Cited: 74
Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer
Lea Daniello, Mariam Elshiaty, Farastuk Bozorgmehr, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 49
Therapeutic Sequencing in ALK+ NSCLC
Mei Elsayed, Petros Christopoulos
Pharmaceuticals (2021) Vol. 14, Iss. 2, pp. 80-80
Open Access | Times Cited: 48
Breaking Bottlenecks for the TCR Therapy of Cancer
Lena Gaissmaier, Mariam Elshiaty, Petros Christopoulos
Cells (2020) Vol. 9, Iss. 9, pp. 2095-2095
Open Access | Times Cited: 46
Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer
Prameela Kandra, Rajender Nandigama, Bastian Eul, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer
Petros Christopoulos, Michal Harel, Kimberly McGregor, et al.
JCO Precision Oncology (2024), Iss. 8
Open Access | Times Cited: 4
Integrated circulating tumour DNA and cytokine analysis for therapy monitoring of ALK-rearranged lung adenocarcinoma
Arlou Kristina Angeles, Florian Janke, Ann-Kathrin Daum, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 1, pp. 112-121
Open Access | Times Cited: 9
Serum cytokines predict efficacy and toxicity, but are not useful for disease monitoring in lung cancer treated with PD-(L)1 inhibitors
Hannah Schindler, Fabienne Lusky, Lea Daniello, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 11
Adoptive cell therapies in thoracic malignancies
Julie Lasvergnas, Marie Naigeon, Kader Chouahnia, et al.
Cancer Immunology Immunotherapy (2022) Vol. 71, Iss. 9, pp. 2077-2098
Closed Access | Times Cited: 9
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas
Hannah Goldschmid, Klaus Kluck, Markus Ball, et al.
Lung Cancer (2023) Vol. 180, pp. 107212-107212
Closed Access | Times Cited: 5
Anaplastic lymphoma kinase-special immunity and immunotherapy
Ye Guo, Hanfei Guo, Yongfei Zhang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 5
Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: confirmatory results from the PROCLAIM phase III clinical trial
Tithi Biswas, Rohin Gawdi, Charulata Jindal, et al.
Journal of Thoracic Disease (2021) Vol. 13, Iss. 10, pp. 5617-5626
Open Access | Times Cited: 7
Can we cure metastatic EGFR-mutated lung cancer today?
Petros Christopoulos
Translational Cancer Research (2023) Vol. 12, Iss. 2, pp. 209-212
Open Access | Times Cited: 2
Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates
Ratoe Suraya, Motoko Tachihara, Tatsuya Nagano, et al.
Cancer Management and Research (2022) Vol. Volume 14, pp. 2079-2090
Open Access | Times Cited: 4
Synergistic Potential of Antigen-Specific Vaccines and Immunomodulatory Agents for Lung Cancer Treatment
Suresh Krishna, Nithya Shree Raman, Karthika Rangasamy, et al.
(2024), pp. 317-330
Closed Access
The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients
Amr Radwan, Chinmay T Jani, Omar Al Omari, et al.
The Oncologist (2024)
Open Access
Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities
Anastasia Ganina, Manarbek Askarov, Larissa Kozina, et al.
Advances in respiratory medicine (2024) Vol. 92, Iss. 6, pp. 504-525
Open Access
Editorial: Systemic immune dysregulation in malignant disease: Insights, monitoring and therapeutic exploitation
Petros Christopoulos, Udo S. Gaipl
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 1
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer
Petros Christopoulos
Translational Lung Cancer Research (2023) Vol. 12, Iss. 7, pp. 1364-1368
Open Access | Times Cited: 1
Double trouble: combined large-cell neuroendocrine and small-cell lung carcinoma
David Fisch, Petros Christopoulos
Translational Cancer Research (2022) Vol. 11, Iss. 9, pp. 3006-3011
Open Access | Times Cited: 2
A novel decision-making tool for first-line treatment selection in metastatic non-small cell lung cancer based on plasma proteome profiling
Petros Christopoulos, Michal Harel, Coren Lahav, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 2
Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives
Hardeep Singh Tuli, Vivek Kumar Garg, Renuka Choudhary, et al.
Molecular Biology Reports (2022) Vol. 50, Iss. 3, pp. 2685-2700
Closed Access | Times Cited: 2
High CENPM Gene Expression Predict Poor Survival Outcome in Lung Adenocarcinoma
Zhe Huang, Nong Yang, Yongchang Zhang
Research Square (Research Square) (2021)
Open Access
Page 1

Scroll to top